Shares of Human Genome (Nasdaq: HGSI) are halted ahead of an FDA panel review of lupus drug Benlysta.

The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE